Intervacc ABFRA:2E9 -1.59%68 Days Payable is 228.98 as of Mar. 2026, which is 96% above its 10-year median of 117.12. GuruFocus rates FRA:2E9 with a GF Score™ of 68/100 and a GF Value™ of €0.08. The stock has 5 warning signs investors should review. Among 702 Biotechnology companies, Intervacc AB ranks worse than 53.13% on this metric.
The historical rank and industry rank for Intervacc AB's Days Payable or its related term are showing as below:
FRA:2E9'
s Days Payable Range Over the Past 10 Years
Min: 53.8 Med: 117.12 Max: 19155.84
Current: 99.3
During the past 12 years, Intervacc AB's highest Days Payable was 19155.84. The lowest was 53.80. And the median was 117.12.
FRA:2E9's Days Payable is ranked worse than 53.13% of 702
companies
in the Biotechnology industry
Industry Median: 113.1
vs FRA:2E9: 99.30
Intervacc AB's Days Payable
declined
from Mar. 2025 (452.14) to Mar. 2026 (228.98).
It may suggest that Intervacc ABaccelerated paying its suppliers.
Intervacc AB Days Payable Related Terms
Intervacc AB Days Payable Historical Data
* Premium members only.
The historical data trend for Intervacc AB's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:2E9 vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Intervacc AB's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Intervacc AB Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Intervacc AB's Days Payable distribution charts can be found below:
* The bar in red indicates where Intervacc AB's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Intervacc AB's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Intervacc AB (FRA:2E9) has a Days Payable of 228.98 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Intervacc AB and its competitors. This is 96% above median its historical median of 117.12. Over the past decade, Intervacc AB's Days Payable has ranged from 53.80 to 19,155.84. According to the industry distribution chart, Intervacc AB ranks #373 out of 702 companies in the Biotechnology industry, placing it in the top 53.1%.
Is Intervacc AB's Days Payable too high?
Intervacc AB's current Days Payable of 228.98 is 96% above median its 10-year median of 117.12. Over the past 10 years, this metric has ranged from a low of 53.80 to a high of 19,155.84. The Biotechnology industry median Days Payable is 113.10. Intervacc AB's value of 228.98 is 102.5% above this industry median. Based on the distribution chart, Intervacc AB ranks #373 out of 702 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Intervacc AB has a GF Score™ of 68/100, reflecting its overall financial health beyond just this single metric.
How does Intervacc AB's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Intervacc AB ranks #373 out of 702 companies for Days Payable. This places Intervacc AB in the lower half of its industry. The industry median Days Payable is 113.10. Intervacc AB's value of 228.98 is 102.5% above this benchmark. Historically, Intervacc AB's own Days Payable has ranged from 53.80 to 19,155.84 over the past decade. While the company's 10-year median is 117.12 vs. the industry median of 113.10, Intervacc AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.10, based on 702 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Intervacc AB's current Days Payable of 228.98 is 102.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Intervacc AB and its competitors. For the Biotechnology industry, the median Days Payable is 113.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Intervacc AB's current Days Payable is 228.98, which is 96% above median its own 10-year median of 117.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Intervacc AB stock overvalued right now?
Intervacc AB (FRA:2E9) has a current Days Payable of 228.98. The stock's GF Value™ is €0.08, compared to a current price of €0.10 — trading 23.5% above its estimated fair value. The current Days Payable is 228.98, which is 96% above median its 10-year median of 117.12 and 102.5% above the Biotechnology industry median of 113.10. Intervacc AB's overall GF Score™ is 68/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Intervacc AB (FRA:2E9), the current Days Payable is 228.98 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Intervacc AB (FRA:2E9) Overvalued in 2026?
Based on GuruFocus' analysis, Intervacc AB stock appears to be overvalued.
The current stock price of €0.10 is trading 23.5% above its estimated GF Value™ of €0.08.
Key valuation signals for FRA:2E9:
Days Payable: 228.98 (96% above median its 10-year median of 117.12)
GF Value™: €0.08 vs. price of €0.10 (23.5% above fair value)
Industry Position: 102.5% above the Biotechnology median (#373 of 702)
No single metric tells the full story. See the FRA:2E9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Intervacc AB is a biotechnology company. It develops new vaccines based on recombinant proteins to meet the increasing need for effective vaccines in animal health care. The company through its subsidiary focuses on diagnostics in the Swedish animal health market and offers bacteriological and mycological analyses on the Swedish market.
68GF Score
Get the complete analysis for FRA:2E9
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:2E9 has been successfully added to your 
